John Reneau

2 clinical trials · Sponsor

Record	Firm	Date
Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma (NCT04848064)	John Reneau	2022-05-06
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma (NCT03409432)	John Reneau	2018-03-16

Every clearance here is in the API, with alerts when new ones post.